Ro Khanna

Showing 3147 articles
Business

CSL's 34% Plunge: A Buying Opportunity or a Value Trap?

After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.

Business

First Hawaiian Bank's Valuation Under Scrutiny Amid Volatile Trading

First Hawaiian Bank (FHB) shares have captured investor interest following a period of mixed performance, trading at $26.55. While recent daily declines contrast with solid monthly and quarterly gains, analysts debate whether the stock's current discount to intrinsic value represents a buying opportunity or reflects underlying economic risks.

Business

Almirall's Valuation Puzzle: Undervalued Gem or Market Mirage?

Shares of Spanish dermatology specialist Almirall (BME:ALM) present a conundrum for investors. While recent trading has been volatile, a key valuation model suggests the stock is trading at a 7.8% discount to its estimated fair value. We examine the bullish case built on its pipeline, the risks it faces, and what the significant gap between its current and forward P/E ratios might signal.